在治疗抑郁障碍中的Bupleurum:综合性审查
Shuzhen Ran1, Rui Peng1, Qingwan Guo1
1Interdisciplinary Institute for Personalized Medicine in Brain Disorders, School of Traditional Chinese Medicine, Jinan University, Guangzhou 510632, China.
Pharmaceuticals (Basel, Switzerland)
|April 27, 2024
概括
布普勒鲁姆是一种传统中医药,通过调节神经递质和大脑因子,显示出抗抑郁药的潜力. 需要进一步的研究来证实它在人类中的有效性和安全性.
科学领域:
- 药理学 药理学是指药理学的学科.
- 神经科学是一个神经科学.
- 传统中国医药 传统中国医药
背景情况:
- 在全球范围内,抑郁症的发病率正在上升,这推动了对新型抗抑郁药疗法的需求.
- 传统中医 (TCM) 提供了潜在的治疗途径,Bupleurum (Chaihu) 历来用于肝脏疾病和作为 Jie Yu (缓解抑郁症) 剂.
- 布普勒的肝脏保护作用和在亚洲国家长期使用以调节情绪,需要进行科学研究.
研究的目的:
- 审查和总结关于Bupleurum抗抑郁药的特性和机制的研究.
- 探索含有Bupleurum的TCM配方在抑郁症治疗中的潜力.
- 要突出关键的生物活性化合物及其分子标.
主要方法:
- 关于Bupleurum及其成分抗抑郁作用的研究文献综述.
- 研究研究作用机制的分析,包括神经递质系统,神经营养因子和细胞内通路.
- 包括传统的中国草药处方和含有Bupleurum的提取物.
主要成果:
- 在Bupleurum中确定了关键的抗抑郁药成分:赛可沙尼A,赛可沙尼D,常规素,皮亚林和奎尔塞丁.
- 证明Bupleurum化合物调节神经递质系统 (血清素,多巴胺),N-甲基-D-酸盐 (NMDA) 系统和来自大脑的神经营养因子 (BDNF).
- 突出了TCM配方的抗抑郁作用,例如含有Bupleurum的Chaihu Shugansan,Xiaoyaosan和Sinisan.
结论:
- 布普勒鲁姆通过各种分子机制表现出显著的抗抑郁药物潜力.
- 结合布普勒鲁姆的TCM配方显示出作为补充或替代抑郁症治疗的希望.
- 进一步的临床研究至关重要,以验证疗效,阐明具体机制,并解决潜在的不良影响和限制.
相关概念视频
01:23Antidepressant Drugs: MAOIs and Other Agents
227
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
227
01:18Depression: Overview
242
Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
242
01:25Antidepressant Drugs: Overview
459
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
459
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
377
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
377
01:28Drug Therapy
43
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
43
01:30Electroconvulsive Therapy
37
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
37